The objective of the Mobility Travel Grant is to strengthen relations between Research Institutions of different European countries. The ESC Working Group on Coronary Pathophysiology & Microcirculation is proud to offer Mobility Travel Grants of €2,500 to selected applicants.
For 2021, and exceptionally, grant applications can be submitted based on a national exchange, where international exchange is not possible due to pandemic mobility restrictions.
2021 Mobility Travel Grant
Congratulations to Dr Stefan Simovic, the winner of the 2021 Mobility Travel Grant of the ESC Working Group on Coronary Pathophysiology & Microcirculation.
2019 Mobility Travel Grant
Congratulations to Ana Vavlukis, the winner of the 2019 Mobility Travel Grant of the ESC Working Group on Coronary Pathophysiology & Microcirculation.
Miss Vavlukis will receive a grant of €2,500 to conduct her PhD project in 2020.
What were your motivations to apply for a grant?
As a young and eager researcher, I have always wanted to broaden my research interests. After drafting my PhD project, I came to realize that one of the crucial steps in the proteomic analysis of LDL-C/non-HDL-C is isolation of the blood lipoproteins, with a methodology that is not yet developed in my country. As a result, I started looking for a place where I can do my separation/isolation and learn the technique enough to transfer and applicate back home.
Being acquainted with the work of Prof. Dr. Lina Badimon and the Catalan Institute of Cardiovascular Sciences, and their expertise in the field of proteomics, I decided to find a way to visit the institution and learn from experts.
My membership in the ESC Working group on Coronary Pathophysiology & Microcirculation led me to the Mobility Travel Grant, which I saw as a unique opportunity to fulfill my research targets. Given that young students, like myself, have limited resources and founds, I could not wait to apply and get a step closer to my study goals.
The PhD research is towards evaluating the statin(s) effects on lipoprotein proteomics in dyslipidemic patients, with the goal of identifying new therapeutic targets and markers for drug therapy monitoring.
Blood samples are obtained from statin-naïve patients at inclusion, and after a 3-month statin treatment. A portion of the blood samples is used for HDL and VLDL/LDL (non-HDL) particle isolation. The isolated lipoproteins will be analyzed with mass spectrometry (after the appropriate sample pre-treatment depending on the type of mass spectrometer used). The identified HDL and VLDL/LDL protein components will be quantified, so we can compare the statin before/after treatment effects. The other portion of the blood samples is used to measure the anti-inflammatory statin actions, by following quantitative concentration changes in specific inflammatory marker levels before and after statin treatment.
The two pleiotropic fields of statin action will be inter-correlated, and, finally, statistically evaluated for a possible association with the established lipid-lowering statin effects, such as LDL-C, non-HDL-C and ApoB lowering.
The 2018 Mobility Travel Grants (MTG) of €2,500 was offered to Mrs. Alina Scarlatescu.